Biomm
BIOM3São Paulo, Brazil· Est.
Brazil’s leading biotech producing insulin and biosimilar biologics for oncology and ophthalmology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Brazil’s leading biotech producing insulin and biosimilar biologics for oncology and ophthalmology.
OncologyOphthalmologyEndocrinology
Technology Platform
Recombinant protein production using CHO mammalian cell lines, enabling high‑yield biosimilar and novel biologic manufacturing.
Opportunities
Expansion of the biosimilar pipeline into immunology and rare diseases, and leveraging Brazil’s policy incentives for domestic biologic production.
Risk Factors
Intensifying competition from multinational biosimilar firms and potential regulatory or reimbursement challenges in the public health system.
Competitive Landscape
Competes with global biosimilar manufacturers entering Brazil and emerging local biotech firms; differentiation lies in its fully national manufacturing base and early ANVISA approvals.